• 3. September 2025

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

ByMerck KGaA

Dez. 22, 2017

Teile den Beitrag mit Freunden